You are here

melanoma

Selecting Anti-Melanoma Drug Targets

Elsevier

Mon, 08/28/17 - 10:24 pm

Exelixis and Genentech hammer out new deal terms

BioPharma Dive

Fri, 07/21/17 - 10:10 am

Bristol Myers Vies to Be King of Immuno-Boosting Cancer Drugs with New Trial Update

TheStreet.com

Thu, 07/6/17 - 09:41 am

Bristol-Myers Squibb

Personalized cancer vaccines vanquish melanoma in small but encouraging study

Stat

Wed, 07/5/17 - 07:04 pm

personalized medicine

Neon Therapeutics

Bristol-Myers’ tarnished checkpoint star Opdivo beats out Yervoy in surprise PhIII

Endpoints

Wed, 07/5/17 - 10:00 am

Bristol-Myers Squibb

Checkmate Pharma Clinches $27M for More Studies in Skin Cancer

Xconomy

Fri, 06/16/17 - 09:28 am

Checkmate Pharmaceuticals

How Far Into the Drug Pipeline Should the FTC Reach?

TheStreet.com

Mon, 05/1/17 - 10:59 am

Array Biopharma

Bristol-Myers Squibb says cancer drug combination 'significantly' improved survival in late-stage melanoma trial

Marketwatch

Tue, 04/4/17 - 11:01 pm

Bristol-Myers Squibb

Why NewLink Genetics Shares Fell 10.3% Today

Motley Fool

Tue, 04/4/17 - 11:00 pm

NewLink Genetics

For Bristol-Myers, A Victory And A Mystery

Forbes

Mon, 04/3/17 - 11:44 am

Bristol-Myers Squibb

Merck, Incyte Expand Cancer Collaboration

Barron's

Fri, 03/31/17 - 10:00 pm

Array walks back its FDA pitch on binimetinib, derailing plans for commercial launch

Endpoints

Mon, 03/20/17 - 09:35 am

Array Biopharma

NRAS-positive melanoma

Roche flags early success for Tecentriq combos, hustles into PhIIIs

Endpoints

Mon, 11/7/16 - 09:10 pm

clinical trials

New Bristol-Myers Squibb Research on Opdivo (nivolumab) Monotherapy and in Combination With Yervoy (ipilimumab) at SMR 2016 Congress Reinforces Immuno-Oncology Leadership and Scientific Expertise in Melanoma

Yahoo

Mon, 10/31/16 - 09:08 am

Bristol-Myers Squibb

These 3 Little Biotechs Just Scored Big

Motley Fool

Tue, 10/11/16 - 09:33 pm

Celldex Therapeutics

renal cell carcinoma

3 Cancer Drugs That Could Get an FDA OK Next Year

Motley Fool

Mon, 10/10/16 - 09:02 am

Clovis Oncology

Array Biopharma

Ariad Pharmaceuticals

non-small cell lung cancer

Merck Announces Longer-Term Follow-Up of Overall Survival Data for KEYTRUDA® (pembrolizumab) in Patients with Advanced Melanoma from KEYNOTE-002 Presented at ESMO 2016 Congress

Yahoo

Sat, 10/8/16 - 03:53 pm

Opdivo: The Oncology Blockbuster for Bristol-Myers Squibb

Market Realist

Tue, 08/23/16 - 09:55 am

Bristol-Myers Squibb

Celldex Rose on Phase 2 Melanoma Data

Market Realist

Wed, 06/8/16 - 05:06 pm

New Data for KEYTRUDA® (pembrolizumab) in Combination with Talimogene Laherparepvec, Dabrafenib Plus Trametinib, or Low-Dose Ipilimumab in Advanced Melanoma Presented at 2016 ASCO Annual Meeting

Yahoo

Sun, 06/5/16 - 11:57 am

Pages